Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 9172157, 11 pages
http://dx.doi.org/10.1155/2016/9172157
Research Article

Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen

1Department of Diabetology & Endocrinology, Kanazawa Medical University, Uchinada, Ishikawa 920-0293, Japan
2Medical Research Institute, Kanazawa Medical University, Uchinada, Ishikawa 920-0293, Japan
3Division of Metabolism and Biosystemic Science, Department of Medicine, Asahikawa Medical University, Midorigaoka Higashi 2-1-1-1, Asahikawa 078-8510, Japan

Received 15 November 2015; Accepted 14 February 2016

Academic Editor: Denis Feliers

Copyright © 2016 Kyoko Nitta et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Xu, K. Kanasaki, M. Kitada, and D. Koya, “Diabetic angiopathy and angiogenic defects,” Fibrogenesis and Tissue Repair, vol. 5, no. 1, article 13, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Kanasaki, G. Taduri, and D. Koya, “Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis,” Frontiers in Endocrinology, vol. 4, article 7, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. E. J. Lewis, L. G. Hunsicker, R. P. Bain, and R. D. Rohde, “The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy,” The New England Journal of Medicine, vol. 329, no. 20, pp. 1456–1462, 1993. View at Publisher · View at Google Scholar · View at Scopus
  4. B. M. Brenner, M. E. Cooper, D. de Zeeuw et al., “Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy,” The New England Journal of Medicine, vol. 345, no. 12, pp. 861–869, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Gæde, H. Lund-Andersen, H.-H. Parving, and O. Pedersen, “Effect of a multifactorial intervention on mortality in type 2 diabetes,” The New England Journal of Medicine, vol. 358, no. 6, pp. 580–591, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Kanasaki, T. Nagai, M. Kitada, D. Koya, and K. Kanasaki, “Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors,” Fibrogenesis and Tissue Repair, vol. 4, no. 1, article 25, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Nagai, K. Nitta, M. Kanasaki, D. Koya, and K. Kanasaki, “The biological significance of angiotensin-converting enzyme inhibition to combat kidney fibrosis,” Clinical and Experimental Nephrology, vol. 19, no. 1, pp. 65–74, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Mauer, B. Zinman, R. Gardiner et al., “Renal and retinal effects of enalapril and losartan in type 1 diabetes,” The New England Journal of Medicine, vol. 361, no. 1, pp. 40–51, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Cheng, W. Zhang, X. Zhang et al., “Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis,” JAMA Internal Medicine, vol. 174, no. 5, pp. 773–785, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Ruggenenti, P. Cravedi, and G. Remuzzi, “Mechanisms and treatment of CKD,” Journal of the American Society of Nephrology, vol. 23, no. 12, pp. 1917–1928, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. H.-Y. Wu, J.-W. Huang, H.-J. Lin et al., “Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis,” British Medical Journal, vol. 347, Article ID f6008, 2013. View at Google Scholar · View at Scopus
  12. G. Wolf and E. Ritz, “Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications,” Kidney International, vol. 67, no. 3, pp. 799–812, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. S. C. W. Tang, J. C. K. Leung, L. Y. Y. Chan, A. A. Eddy, and K. N. Lai, “Angiotensin converting enzyme inhibitor but not angiotensin receptor blockade or statin ameliorates murine adriamycin nephropathy,” Kidney International, vol. 73, no. 3, pp. 288–299, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Nagai, M. Kanasaki, S. P. Srivastava et al., “N-acetyl-seryl-aspartyl-lysyl-proline inhibits diabetes-associated kidney fibrosis and endothelial-mesenchymal transition,” BioMed Research International, vol. 2014, Article ID 696475, 12 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Kanasaki, T. Nagai, K. Nitta, M. Kitada, and D. Koya, “N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes,” Frontiers in Pharmacology, vol. 5, article 70, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Azizi, A. Rousseau, E. Ezan et al., “Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline,” Journal of Clinical Investigation, vol. 97, no. 3, pp. 839–844, 1996. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Kanasaki, D. Koya, T. Sugimoto, M. Isono, A. Kashiwagi, and M. Haneda, “N-acetyl-seryl-aspartyl-lysyl-proline inhibits TGF-β mediated plasminogen activator inhibitor-1 expression via inhibition of Smad pathway in human mesangial cells,” Journal of the American Society of Nephrology, vol. 14, no. 4, pp. 863–872, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Pokharel, S. Rasoul, A. J. M. Roks et al., “N-Acetyl-Ser-Asp-Lys-Pro inhibits phosphorylation of Smad2 in cardiac fibroblasts,” Hypertension, vol. 40, no. 2, pp. 155–161, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Shibuya, K. Kanasaki, M. Isono et al., “N-acetyl-seryl-aspartyl-lysyl-proline prevents renal insufficiency and mesangial matrix expansion in diabetic db/db mice,” Diabetes, vol. 54, no. 3, pp. 838–845, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Omata, H. Taniguchi, D. Koya et al., “N-acetyl-seryl-asparlyl-lysyl-proline ameliorates the progression of renal dysfunction and fibrosis in WKY rats with established anti-glomerular basement membrane nephritis,” Journal of the American Society of Nephrology, vol. 17, no. 3, pp. 674–685, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. J.-M. Liu, F. Lawrence, M. Kovacevic et al., “The tetrapeptide AcSDKP, an inhibitor of primitive hematopoietic cell proliferation, induces angiogenesis in vitro and in vivo,” Blood, vol. 101, no. 8, pp. 3014–3020, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. D. Wang, O. A. Carretero, X.-Y. Yang et al., “N-acetyl-seryl-aspartyl-lysyl-proline stimulates angiogenesis in vitro and in vivo,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 287, no. 5, pp. H2099–H2105, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Fromes, J.-M. Liu, M. Kovacevic, J. Bignon, and J. Wdzieczak-Bakala, “The tetrapeptide acetyl-serine-aspartyl-lysine-proline improves skin flap survival and accelerates wound healing,” Wound Repair and Regeneration, vol. 14, no. 3, pp. 306–312, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Huff, C. S. G. Müller, A. M. Otto, R. Netzker, and E. Hannappel, “β-thymosins, small acidic peptides with multiple functions,” International Journal of Biochemistry and Cell Biology, vol. 33, no. 3, pp. 205–220, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. V. Koutrafouri, L. Leondiadis, K. Avgoustakis et al., “Effect of thymosin peptides on the chick chorioallantoic membrane angiogenesis model,” Biochimica et Biophysica Acta (BBA)—General Subjects, vol. 1568, no. 1, pp. 60–66, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. D. Philp, T. Huff, Y. S. Gho, E. Hannappel, and H. K. Kleinman, “The actin binding site on thymosin beta4 promotes angiogenesis,” The FASEB Journal, vol. 17, no. 14, pp. 2103–2105, 2003. View at Google Scholar · View at Scopus
  27. K. M. Malinda, A. L. Goldstein, and H. K. Kleinman, “Thymosin β4 stimulates directional migration of human umbilical vein endothelial cells,” The FASEB Journal, vol. 11, no. 6, pp. 474–481, 1997. View at Google Scholar · View at Scopus
  28. N. Smart, C. A. Risebro, A. A. D. Melville et al., “Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization,” Nature, vol. 445, no. 7124, pp. 177–182, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. K. Kanasaki, M. Haneda, T. Sugimoto et al., “N-acetyl-seryl-aspartyl-lysyl-proline inhibits DNA synthesis in human mesangial cells via up-regulation of cell cycle modulators,” Biochemical and Biophysical Research Communications, vol. 342, no. 3, pp. 758–765, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Sugimoto, G. Grahovac, M. Zeisberg, and R. Kalluri, “Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors,” Diabetes, vol. 56, no. 7, pp. 1825–1833, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. K. Kanasaki, S. Shi, M. Kanasaki et al., “Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen,” Diabetes, vol. 63, no. 6, pp. 2120–2131, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Shi, S. P. Srivastava, M. Kanasaki et al., “Interactions of DPP-4 and integrin β1 influences endothelial-to-mesenchymal transition,” Kidney International, vol. 88, no. 3, pp. 479–489, 2015. View at Publisher · View at Google Scholar
  33. S. Mackensen-Haen, R. Bader, K. E. Grund, and A. Bohle, “Correlations between renal cortical interstitial fibrosis, atrophy of the proximal tubules and impairment of the glomerular filtration rate,” Clinical Nephrology, vol. 15, no. 4, pp. 167–171, 1981. View at Google Scholar · View at Scopus
  34. K. A. Nath, “Tubulointerstitial changes as a major determinant in the progression of renal damage,” American Journal of Kidney Diseases, vol. 20, no. 1, pp. 1–17, 1992. View at Publisher · View at Google Scholar · View at Scopus
  35. R. A. Risdon, J. C. Sloper, and H. E. de Wardener, “Relationship between renal function and histological changes found in renal biopsy specimens from patients with persistent glomerular nephritis,” The Lancet, vol. 2, no. 7564, pp. 363–366, 1968. View at Google Scholar · View at Scopus
  36. L. I. Schainuck, G. E. Striker, R. E. Cutler, and E. P. Benditt, “Structural-functional correlations in renal disease. Part II: the correlations,” Human Pathology, vol. 1, no. 4, pp. 631–641, 1970. View at Publisher · View at Google Scholar · View at Scopus
  37. G. E. Striker, L. I. Schainuck, R. E. Cutler, and E. P. Benditt, “Structural-functional correlations in renal disease. Part I: a method for assaying and classifying histopathologic changes in renal disease,” Human Pathology, vol. 1, no. 4, pp. 615–630, 1970. View at Publisher · View at Google Scholar · View at Scopus
  38. K. Kanasaki, M. Kitada, and D. Koya, “Pathophysiology of the aging kidney and therapeutic interventions,” Hypertension Research, vol. 35, no. 12, pp. 1121–1128, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. K. Sharma, J. H. Ix, A. V. Mathew et al., “Pirfenidone for diabetic nephropathy,” Journal of the American Society of Nephrology, vol. 22, no. 6, pp. 1144–1151, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. D. de Zeeuw, T. Akizawa, P. Audhya et al., “Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease,” The New England Journal of Medicine, vol. 369, no. 26, pp. 2492–2503, 2013. View at Publisher · View at Google Scholar · View at Scopus